BNR:NSD-Burning Rock Biotech Limited (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 28.85

Change

-1.00 (-3.35)%

Market Cap

USD 2.73B

Volume

0.25M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for tissue samples; OncoCompass IO, the corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and OncoScreen ParpMatch and OncoCompass ParpMatch to target critical genes associated with homologous recombination deficiency. The company also offers LungCore for lung cancer, ProstrateCore for prostrate cancer, BreastCore for breast cancer, LymphPlasma for lymphomas, and ThyroCare for thyroid cancer. In addition, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China. Burning Rock Biotech Limited has collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, Sino Biopharm, CStone and BeiGene. The company was founded in 2014 and is headquartered in Guangzhou, China.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-13 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

+0.61 (+0.16%)

USD54.43B 87.11 49.27
IDXX IDEXX Laboratories, Inc

+5.76 (+1.12%)

USD43.69B 65.93 50.99
DXCM DexCom, Inc

-9.52 (-2.85%)

USD32.25B 64.07 83.72
OZON Ozon Holdings PLC

-0.65 (-1.19%)

USD22.21B N/A N/A
EXAS Exact Sciences Corporation

-2.45 (-2.55%)

USD16.46B N/A N/A
ICLR ICON Public Limited Company

+2.82 (+1.26%)

USD11.86B 35.32 24.09
GH Guardant Health, Inc

-4.16 (-3.65%)

USD11.52B N/A N/A
PRAH PRA Health Sciences, Inc

+1.79 (+1.05%)

USD11.02B 52.02 26.60
SYNH Syneos Health, Inc

+0.28 (+0.33%)

USD8.86B 45.20 22.00
NTRA Natera, Inc

+1.76 (+2.02%)

USD7.67B N/A N/A

ETFs Containing BNR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.89% 75% C 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.89% 75% C 77% C+
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 2.73B 73% C 78% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio -99,999.99 100% A+ 93% A
Price/Book Ratio 7.26 37% F 22% F
Price / Cash Flow Ratio -37.16 92% A- 90% A-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -26.44% 56% F 33% F
Return on Invested Capital -50.62% 33% F 16% F
Return on Assets -14.68% 44% F 24% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.80 43% F 31% F
Short Percent N/A N/A N/A N/A N/A
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector